OverviewSuggest Edit

Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder, and Fanapt (iloperidone), a product for the treatment of schizophrenia. The Company also has several clinical development products.

TypePublic
Founded2002
HQWashington, US
Websitevandapharma.com
Employee Ratings2

Latest Updates

Employees (est.) (Dec 2018)270(-1%)
Job Openings24
Revenue (FY, 2018)$193.1 M(+17%)
Share Price (Jun 2019)$13.6 (-2%)

Key People/Management at Vanda Pharmaceuticals

Mihael H. Polymeropoulos

Mihael H. Polymeropoulos

CEO
James Kelly

James Kelly

CFO
Robert Repella

Robert Repella

CCO
Paolo Baroldi

Paolo Baroldi

Vice-President
Show more

Vanda Pharmaceuticals Office Locations

Vanda Pharmaceuticals has offices in Washington, Berlin and London
Washington, US (HQ)
The Avenue, 2200 Pennsylvania Ave NW #300E
Berlin, DE
Französische Straße 12 c/o Satellite Office
London, GB
Tower 42, 21st Floor, 21A 25 Old Broad Street
Show all (3)

Vanda Pharmaceuticals Financials and Metrics

Vanda Pharmaceuticals Revenue

Vanda Pharmaceuticals's revenue was reported to be $193.12 m in FY, 2018
USD

Revenue (Q1, 2019)

47.7m

Net income (Q1, 2019)

(612.0k)

EBIT (Q1, 2019)

(2.1m)

Market capitalization (10-Jun-2019)

722.4m

Closing stock price (10-Jun-2019)

13.6

Cash (31-Mar-2019)

34.4m
Vanda Pharmaceuticals's current market capitalization is $722.4 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

33.9m109.9m146.0m165.1m193.1m

Cost of goods sold

23.5m

Gross profit

86.5m

Gross profit Margin, %

79%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

8.7m9.1m10.9m14.8m22.2m27.6m28.3m33.3m36.0m38.5m37.4m42.1m41.3m43.6m47.4m49.1m47.7m

Cost of goods sold

198.0k703.0k5.0m5.8m6.5m6.0m6.5m7.0m

Gross profit

10.7m14.1m17.1m21.8m21.8m27.3m29.5m31.5m

Gross profit Margin, %

98%95%77%79%77%82%82%82%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

64.8m60.9m50.8m40.4m33.6m61.0m

Accounts Receivable

2.0m3.7m16.3m20.3m17.6m28.8m

Inventories

2.7m3.1m1.3m779.0k840.0k994.0k

Current Assets

135.6m141.7m166.5m174.2m169.9m299.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.3m)20.2m(39.9m)(18.0m)(15.6m)25.2m

Depreciation and Amortization

582.0k935.0k1.2m1.4m

Inventories

1.3m3.0m387.0k200.0k(1.1m)70.0k

Accounts Payable

374.0k174.0k9.4m575.0k6.0m(618.0k)
Quarterly
USDY, 2019

Financial Leverage

1.3 x
Show all financial metrics

Vanda Pharmaceuticals Online and Social Media Presence

Embed Graph

Vanda Pharmaceuticals News and Updates

Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

WASHINGTON, June 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 19, 2019 at 2:00 p.m. Eastern Time. The corporate...

Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors

WASHINGTON, April 24, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019. Following Ms. Chrousos' appointment, Vanda's Board of Directors is now comprised of six...

Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019

WASHINGTON, April 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 1, 2019,...

Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Investors of April 26, 2019 Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

SAN FRANCISCO, April 3, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) of the April 26, 2019 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Vanda securities between ...

RM LAW Announces Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

BERWYN, Pa., Feb. 28, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA) between November 4, 2015 and February 11, 2019, inclusive...

Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results

WASHINGTON, Feb. 13, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2018. "The combination of strong commercial performance and positive clinical results has...
Show more

Vanda Pharmaceuticals Frequently Asked Questions

  • When was Vanda Pharmaceuticals founded?

    Vanda Pharmaceuticals was founded in 2002.

  • Who are Vanda Pharmaceuticals key executives?

    Vanda Pharmaceuticals's key executives are Mihael H. Polymeropoulos, James Kelly and Robert Repella.

  • How many employees does Vanda Pharmaceuticals have?

    Vanda Pharmaceuticals has 270 employees.

  • What is Vanda Pharmaceuticals revenue?

    Latest Vanda Pharmaceuticals annual revenue is $193.1 m.

  • What is Vanda Pharmaceuticals revenue per employee?

    Latest Vanda Pharmaceuticals revenue per employee is $715.3 k.

  • Who are Vanda Pharmaceuticals competitors?

    Competitors of Vanda Pharmaceuticals include AstraZeneca, Xencor and Axsome Therapeutics.

  • Where is Vanda Pharmaceuticals headquarters?

    Vanda Pharmaceuticals headquarters is located at The Avenue, 2200 Pennsylvania Ave NW #300E, Washington.

  • Where are Vanda Pharmaceuticals offices?

    Vanda Pharmaceuticals has offices in Washington, Berlin and London.

  • How many offices does Vanda Pharmaceuticals have?

    Vanda Pharmaceuticals has 3 offices.